Contact information
sarah.pearson@oncology.ox.ac.uk
01865 617010
octo-enquiries@oncology.ox.ac.uk
https://www.oncology.ox.ac.uk/research/srf/oncology-clinical-trials-office-octo
https://orcid.org/0000-0001-5386-1953
OCTO, Department of Oncology, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford, United Kingdom, OX3 7DQ
Sarah Pearson
BSc
OCTO Trial Management Director
OCTO Trial Management Director
After a degree in Human Biology I worked on various cancer epidemiology and genetics projects. Driven by an interest to work in research with a more direct impact on cancer patient care, I joined OCTO as a Clinical Trial Coordinator in 2004, became a project manager in 2007 and the group’s Trial Management Director in 2008. The role involves leading the operational activity in the CTU including the specialist teams which design and deliver a broad portfolio of CTIMPs, non-CTIMPs and device trials.
I led the OCTO team through a merger with other Oxford CTUs which created the UKCRC Registered CTU OCTRU, and have adapted the operational structures from supporting late phase trials to delivery of early phase (FIH to phase II) trials and more recently into early detection and precision prevention.
Recent publications
-
Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.
Journal article
Nicholson BD. et al, (2023), Lancet oncol, 24, 733 - 743
-
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article
Kerr RS. et al, (2016), Lancet oncol, 17, 1543 - 1557
-
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Journal article
Dutton SJ. et al, (2014), Lancet oncol, 15, 894 - 904
-
Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.
Journal article
Nicum S. et al, (2013), Journal of clinical oncology, 31